The Insider: Meet the CEOs – 16 February

Prescient Therapeutics is a clinical-stage oncology company focused on developing novel, personalised therapies for a range of cancers. The company is conducting ongoing clinical trials and manufacturing for its PTX-100 and PTX-200 targeted cancer therapies. Prescient has collaborated with the world-leading Peter Mac cancer centre to develop a next-generation OmniCAR cell therapy that is capable of reshaping cancer treatment. In December 2021, the company announced a strong cash position of $14.77 million and newly gained accreditation that enables clinical studies for OmniCAR.

Global Health is one of Australia’s longest established and most experienced developers of software applications for the healthcare industry. The company is recognised for its innovation of leading edge solutions, including its software-as-a-service product suite and a mobile application for in-home care. Global Health had a strong FY21 growing its revenue 20% to $7.48 million with an adjusted EBITDA of $1.05 million; more than double the previous corresponding period. After successfully raising a combined $7.6 million in August 2021, the company is targeting 25% annual growth over the next three years expanding in Victoria and growing interstate.

Ensurance is the holding company that owns three distinct businesses in the insurance industry: an insurance brokerage, an underwriting agency and an IT company. The company increased its gross written insurance premiums by 70% year-on-year to $29 million for the first half of FY22 and has experienced record revenue growth of 35% in the December 2021 quarter on the previous corresponding period. In FY21, Ensurance UK achieved its first annual profit since its incorporation, with over $185,000 of profit being reported. In the same period, the company also acquired a boutique underwriting agency with a network of 70+ insurance broking houses, and insurance premiums under management in excess of $10 million.